Published Manuscripts
Information and study results included in the publications below are based on the CureGN Study.
Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators
In patients with membranous nephropathy treated with cyclosporine or rituximab in the MENTOR trial, we found that the optimal method to evaluate risk factors for the probability of treatment response was to use anti-PLA2R antibody levels combined with albumin levels after 3 months of treatment, which was significantly better than using antibody levels alone or risk factor evaluation at baseline, with no added benefit of waiting until 6 months of treatment.
Palmer MB, Royal V, Jennette JC, Smith AR, Liu Q, Ambruzs JM, Andeen NK, D'Agati VD, Fogo AB, Gaut J, Gbadegesin RA, Greenbaum LA, Hou J, Helmuth ME, Lafayette RA, Liapis H, Robinson B, Stokes MB, Twombley K, Yin H, Nast CC; CureGN Consortium
Marchel D, Trachtman H, Larkina M, Helmuth M, Lai Yee JY, Fermin D, Bomback AS, Canetta PA, Gipson DS, Mottl AK, Parekh RS, Saha MK, Sampson MG, Lafayette RA, Mariani LH; Nephrotic Syndrome Study Network (NEPTUNE); Cure Glomerulonephropathy (CureGN)
Hematuria is prevalent among participants with the three podocytopathies and is significantly and independently associated with worse kidney-related outcomes, including both progressive loss of kidney function and remission of proteinuria.
Wang CS, Glenn DA, Helmuth M, Smith AR, Bomback AS, Canetta PA, Coppock GM, Khalid M, Tuttle KR, Bou-Matar R, Greenbaum LA, Robinson BM, Holzman LB, Smoyer WE, Rheault MN, Gipson D, Mariani LH; Cure Glomerulonephropathy (CureGN) Study Consortium
In this cohort study of 2,055 patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy, COVID-19 resulted in hospitalization or death for 1 in 8 cases and was associated with a 35% increase in risk for worsening proteinuria. By contrast, vaccination did not appear to adversely affect kidney function or proteinuria. Our data support vaccination for COVID-19 in patients with glomerular disease.
Mottl AK, Bomback AS, Mariani LH, Coppock G, Jennette JC, Almaani S, Gipson DS, Kelley S, Kidd J, Laurin LP, Mucha K, Oliverio A, Palmer M, Rizk D, Sanghani N, Stokes MB, Susztak K, Wadhwani S, Nast CC
CureGN-Diabetes, an ancillary study to CureGN, seeks to understand how diabetes influences the diagnosis, treatment, and outcomes of GD.
Kallash M, Wang Y, Smith A, Trachtman H, Gbadegesin R, Nester C, Canetta P, Wang C, Hunley TE, Sperati CJ, Selewski D, Ayoub I, Srivastava T, Mottl AK, Kopp J, Gillespie B, Robinson B, Chen D, Steinke K, Twombley K, Reidy K, Mucha K, Greenbaum L, Blazius B, Helmuth M, Yonatan P, Parekh RS, Hogan S, Royal V, D'Agati V, Chishti A, Falk R, Gharavi A, Holzman L, Klein J, Smoyer W, Kretzler M, Gipson D, Kidd JM, CureGN
In patients with FSGS, high-risk APOL1 genotype is the predominant factor associated with more rapid loss of kidney function.
Dhruti P Chen, Candace D Henderson, Jaeline Anguiano, Claudia P Aiello, Mary M Collie Vanessa Moreno, Yichun Hu, Susan L Hogan, Ronald J Falk; CureGN
The prevalence of high-risk APOL1 variant among Black membranous nephropathy participants is comparable with the general Black population (10%-15%), yet the high-risk genotype was associated with worse eGFR decline and faster time to kidney failure compared with low-risk genotype and participants that were not Black.
Eman Abdelghani, Amanda P Waller, Katelyn J Wolfgang, Joseph R Stanek, Samir V Parikh, Brad H Rovin, William E Smoyer, Bryce A Kerlin; the PNRC Investigators, the NEPTUNE Investigators
These data suggest that AT deficiency plays only a limited role in the mechanisms underlying the acquired hypercoagulopathy of nephrotic syndrome. Moreover, AT deficiency was not present in all patients with nephrotic syndrome and was more likely in children than adults despite the higher risk for venous thromboembolism in adults than children.
Monica L Reynolds, Andrea L Oliverio, Jarcy Zee, Elizabeth M Hendren, Michelle M O'Shaughnessy, Isabelle Ayoub, Salem Almaani, Tetyana L Vasylyeva, Katherine E Twombley, Shikha Wadhwani, Julia M Steinke, Dana V Rizk, Meryl Waldman, Margaret E Helmuth, Carmen Avila-Casado, Nada Alachkar, Carla M Nester, Vimal K Derebail, Michelle A Hladunewich, Laura H Mariani
Preeclampsia increases the risk for future chronic kidney disease (CKD). Among those diagnosed with CKD, it is unclear whether a prior history of preeclampsia, or other complications in pregnancy, negatively impact kidney disease progression. In this longitudinal analysis, we assessed kidney disease progression among women with glomerular disease with and without a history of a complicated pregnancy.
Chen DP, Helmuth ME, Smith AR, Canetta PA,Ayoub I, Mucha K, Kallash M, Kopp J, Gbadegesin R, Gillespie BW, Greenbaum LA,Parekh RS, Hunley T, Sperati CJ, Selewski DT, Kidd J, Chishti A, Reidy K, MottlA, Gipson DS, Srivastava T, Twombley KE; CureGN Consortium
Ravipati P, Freese RL, Royal V, Bu L, Canetta PA, Gipson DS, Kallash M, Kiryluk K, Nast C, Reich HN, Rheault MN, Saha M, Nachman PH
Glenn DA, Zee J, Mansfield SA, O’Shaughnessy MM, BombackAS, Gibson K, Greenbaum LA, Mariani LH, Falk RJ, Hogan S, Mottl AK, Denburg MR, CureGN
Krissberg KR, O’Shaughnessy MM, Smith AR, Helmuth ME, AlmaaniS, Aviles DH, Brathwaite KE, Cai Y, Cattran D, Gbadegesin RA, Glenn DA,Greenbaum LA, Iragorri S, Jain K, Khalid M, Kidd J, Kopp J, Lafayette R, LaneJC, Lugani F, Nestor JG, Rarekh RS, Reidy K, Selewski DT, Sethna CB, SperatiCJ, Tuttle J, Twombley KE, Vasylyeva TL, Weaver DJ, Wenderfer SE, Gibson KL,CureGN
Glenn DA, Zee J, Hegde A, Henderson C, O'ShaughnessyMM, Bomback A, Gibson K, Greenbaum LA, Mansfield S, Hu Y, Mariani L, Falk R,Hogan S, Denburg M, Mottl A
Krissberg JR, Helmuth ME, Almaani S, Cai Y, Cattran D, Chatterjee D, Gbadegesin RA, Gibson KL, Glenn DA, Greenbaum LA, Iragorri S, Jain K, Khalid M, Kidd JM, Kopp JB, Lafayette R, Nestor JG, Parekh RS, Reidy KJ, Selewski DT, Sperati JC, Tuttle KR, Twombley K, Vasylyeva TL, Weaver JD, Wenderfer SE, O'Shaughnessy MM
Gillespie BW, Laurin LP, Zinsser D, Lafayette R,Marasa M, Wenderfer SE, Vento S, Poulton C, Barisoni L, Zee J, Helmuth M, LuganiF, Kamel M, Hill-Callahan P, Hewitt SM, Mariani LH, Smoyer WE, Greenbaum LA,Gipson DS, Robinson BM, Gharavi AG, Guay-Woodford LM, Trachtman H
Glenn DA, Henderson CDm O'Shaughnessy M, Hu Y, Bomback A, Gibson K, Greenbaum LA, Zee J, Mariani L, Falk R, Hogan, S, Mottl A; CureGN Consorium.
Murphy SL, Mahan JD, Troost JP, Srivastava T,Kogon AJ, Cai Y, Davis TK, Fernandez H, Fornoni A, Gbadegesin RA, Herreshoff E,Canetta PA, Nachman PH, Reeve BB, Selewski DT, Sethna CB, Wang CS, Bartosh SM,Gipson DS, Tuttle KR; CureGN Consortium
Barisoni L, Lafata KJ, Hewitt SM, Madabhushi A, Balis UGJ
Delbarba E, Marasa M, Canetta PA, Piva SE, Chatterjee D, Kil BH, Mu X, Gibson KL, Hladunewich MA, Hogan JJ, Julian BA, Kidd JM, Laurin LP, Nachman PH, Rheault MN, Rizk DV, Sanghani NS, Trachtman H, Wenderfer SE, Gharavi AG, Bomback AS, Cure GN Consortium
O'Shaughnessy MM, Troost JP, Bomback AS, Hladunewich MA, Ashoor IF,Gibson KL, Matar RB, Selewski DT, Srivastava T, Rheault MN, Al-Uzri A, KogonAJ, Khalid M, Vento S, Sanghani NS, Gillespie BW, Gipson DS, Wang CS, Parsa A,Guay-Woodford L, Laurin LP
Ashoor IF, Mansfield S, O'Shaughnessy MM, Parekh RS, Zee J, Vasylyeva TL, Kogon A, Sethna CB, Glenn DA, Chishti AS, Weaver DJ, Helmuth M, Fernandez HE, Rheault MN
Canetta PA, Troost JP, Mahoney S, Kogon AJ, Carlozzi N, Bartosh SM, Cai Y, Davis TK, Fernandez H, Farnoni A, Gbadegesin RA, Herreshoff E, Mahan JD, Nachman PH, Selewski DT, Sethna CB, Srivastava T, Tuttle KR, Wang C, Falk RJ, Gharavi AG, Gillespie BW, Greenbaum LA, Holtzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM, Reeve B, Gipson DS
Hendren EM and Reynolds ML, Mariani LH, Zee J, Moore NW, O'Shaughnessy MM, Oliverio AL, Hill-Callahan P, Rizk DV, Almanni S, Twombley KE, Herreshoff E, Nester CA, Hladunewich MA
Mariani LH, Bomback AS, Canetta PA, Flessner MF, Helmuth M, Hladunewich MA, Hogan JJ, Kiryluk K, Nachman PH, Nast C, Rheault MN, Rizk DV, Trachtman H, Wenderfer SE, Bowers C, Hill-Callahan P, Marasa M*, Poulton CJ, Revell A, Vento S, Barisoni L, Cattran D, D'agati V, Jennette JC, Klein JB, Laurin LP, Twombley K, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson B, Smoyer WE, Guay-Woodford LM
Oliverio AL, Zee J, Mariani LH, Reynolds ML*, O'Shaughnessy MM*, Hendren EM*, Alachkar N, Herreshoff E, Rizk DV, Nester CM, Steinke J, Twombley EK, Hladunewich MA
Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, Cattran DC, Chishti AS, D'Agati VD, D'Alessandri-Silva CJ, Gbadegesin RA, Hogan JJ, Iragorri S, Jennette JC, Julian BA, Khalid M*, Lafayette RA, Liapis H, Lugani F, Mansfield SA, Mason S, Nachman PH, Nast CC, Nester CM, Noone DG*, Novak J, O'Shaughnessy MM*, Reich HN, Rheault MN, Rizk DV, Saha MK*, Sanghani NS, Sperati CJ, Sreedharan R, Srivastava T, Swaitecka-Urban A, Twombley K, Vasylyeva TL, Weaver DJ, Yin H, Zee J, Falk RJ, Gharavi AG, Gillespie BW, Gipson DS, Greenbaum LA, Holzman LB, Kretzler M, Robinson BM, Smoyer WE, Flessner M, Guay-Woodford LM, Kiryluk K
